[1]盖守娟.细胞周期蛋白依赖性激酶抑制因子2A基因表达与胰腺癌临床病理特征的关系[J].新乡医学院学报,2021,38(6):573-576.[doi:10.7683/xxyxyxb.2021.06.016]
　GAI Shoujuan.Relationship between the expression of cyclin-dependent kinase inhibitor 2A gene and clinicopathological features of pancreatic cancer[J].Journal of Xinxiang Medical University,2021,38(6):573-576.[doi:10.7683/xxyxyxb.2021.06.016]
点击复制

细胞周期蛋白依赖性激酶抑制因子2A基因表达与胰腺癌临床病理特征的关系
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
38
期数:
2021年6
页码:
573-576
栏目:
临床研究
出版日期:
2021-06-05

文章信息/Info

Title:
Relationship between the expression of cyclin-dependent kinase inhibitor 2A gene and clinicopathological features of pancreatic cancer
作者:
盖守娟
（朝阳市第二医院消化内科，辽宁　朝阳　122000）
Author(s):
GAI Shoujuan
(Department of Gastroenterology,the Second Hospital of Chaoyang,Chaoyang 122000,Liaoning Province,China)
关键词:
细胞周期蛋白依赖性激酶抑制因子2A; 胰腺癌; 临床病理特征
Keywords:
cyclin-dependent kinase inhibitor 2Apancreatic cancerclinicopathological features
分类号:
R735.9
DOI:
10.7683/xxyxyxb.2021.06.016
文献标志码:
A
摘要:
目的　探讨细胞周期蛋白依赖性激酶抑制因子2A（CDKN2A）基因表达与胰腺癌（PC）临床病理特征的关系。方法　选择2016年1月至2018年6月朝阳市第二医院保存的88例PC组织标本和30例正常胰腺组织标本，采用定量反转录聚合酶链反应法检测PC组织和正常胰腺组织中CDKN2A mRNA表达，分析CDKN2A基因表达与PC临床病理特征及患者2 a总生存率和疾病无进展生存率的关系。结果　PC组织和正常胰腺组织中CDKN2A mRNA相对表达量分别为1.43±0.56、2.03±0.87，PC组织中CDKN2A mRNA相对表达量显著低于正常胰腺组织（P＜0.05）。以正常胰腺组织中CDKN2A mRNA相对表达量均值2.03为界值，PC组织中CDKN2A基因高表达者36例，低表达者52例。CDKN2A基因高表达与低表达患者的性别、年龄、肿瘤部位比较差异无统计学意义（P>0.05），CDKN2A基因高表达与低表达患者的肿瘤直径、组织分化程度和肿瘤临床分期比较差异有统计学意义（P＜0.05）。CDKN2A mRNA高表达和低表达患者2 a总生存率分别为66.67%（24/36）、34.62%（18/52），2 a疾病无进展生存率分别为58.33%（21/36）、23.08%（12/52）；CDKN2A mRNA低表达患者2 a总生存率和2 a疾病无进展生存率显著低于高表达患者（P＜0.05）。结论　PC组织中CDKN2A基因表达下调，且CDKN2A基因表达与肿瘤大小、组织分化程度、肿瘤临床分期及患者生存状况有关。
Abstract:
Objective　To investigate the relationship between the expression of cyclin-dependent kinase inhibitor 2A (CDKN2A) gene and clinicopathological features of pancreatic cancer (PC).Methods　　Eighty-eight specimens of PC cancer and thirty normal pancreatic tissues in the Second Hospital of Chaoyang from January 2016 to June 2018 were collected.The expression of CDKN2A mRNA in PC tissues and normal pancreatic tissues was detected by quantitative reverse transcription polymerase chain reaction.The relationship between the expression of CDKN2A gene and clinicopathological features of PC,2-year overall survival rate and progression free survival rate of patients with PC was analyzed.Results　The relative expression of CDKN2A mRNA in PC tissues and normal pancreatic tissues was 1.43±0.56 and 2.03±0.87,respectively.The relative expression of CDKN2A mRNA in PC tissues was significantly lower than that in normal pancreatic tissues (P<0.05).The average relative expression of CDKN2A mRNA in normal pancreatic tissue was 2.03.Taking 2.03 as the cut-off value,there were 36 cases with high expression of CDKN2A gene and 52 cases with low expression of CDKN2A gene in PC tissues.There was no significant difference in gender,age and tumor location between CDKN2A high expression and low expression patients (P>0.05).There were significant differences in tumor diameter,histological differentiation and clinical stage between CDKN2A high expression and low expression patients (P<0.05).The 2-year overall survival rate in patients with high expression and low expression of CDKN2A mRNA was 66.67% (24/36) and 34.62% (18/52),respectively;and the 2-year progression-free survival rate was 58.33% (21/36) and 23.08% (12/52),respectively.The 2-year overall survival rate and 2-year disease progression-free survival rate of patients with low expression of CDKN2A mRNA were significantly lower than those of patients with high expression of CDKN2A mRNA (P<0.05).Conclusion　CDKN2A gene expression is down-regulated in PC tissues,and the expression of CDKN2A gene is related to the tumor size,tissue differentiation,clinical stage and survival status of patients.

参考文献/References:

［1］　SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2019［J］.CA Cancer J Clin,2019,69(1):7-34.
［2］　LU C,XU C F,WAN X Y,et al.Screening for pancreatic cancer in familial high-risk individuals:a systematic review［J］.World J Gastroenterol,2015,21(28):8678-8686.
［3］　ZHEN D B,RABE K G,GALLINGER S,et al.BRCA1,BRCA2,PALB2,and CDKN2A mutations in familial pancreatic cancer:a PACGENE study［J］.Genet Med,2015,17(7):569-577.
［4］　MCWILLIAMS R R,WIEBEN E D,CHAFFEE K G,et al.CDKN2A germline rare coding variants and risk of pancreatic cancer in minority populations［J］.Cancer Epidemiol Biomarkers Prev,2018,27(11):1364-1370.
［5］　CAMPA D,PASTORE M,GENTILUOMO M,et al.Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk［J］.Oncotarget,2016,7(35):57011-57020.
［6］　LEOF E R,ZHU X,RABE K G,et al.Pancreatic cancer and melanoma related perceptions and behaviors following disclosure of CDKN2A variant status as a research result［J］.Genet Med,2019,21(11):2468-2477.
［7］　熊慧敏，许小凡，段丽芳，等.白细胞介素-6在胰腺炎症和肿瘤中的作用机制研究进展［J］.新乡医学院学报，2019，36（12）：1191-1196.
［8］　GRANT R C,SELANDER I,CONNOR A A,et al.Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer［J］.Gastroenterology,2015,148(3):556-564.
［9］　HUANG J Y,BUTLER L M,WANG R,et al.Dietary intake of one-carbon metabolism-related nutrients and pancreatic cancer risk:the Singapore Chinese health study［J］.Cancer Epidemiol Biomarkers Prev,2016,25(2):417-424.
［10］　SASAKI S,KITAGAWA Y,SEKIDO Y,et al.Molecular processes of chromosome 9p21 deletions in human cancers［J］.Oncogene,2003,22(24):3792-3798.
［11］　GUL A,LEYLAND-JONES B,DEY N,et al.A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positivebreast cancer:a genomic algorithm-based treatment approach［J］.Am J Cancer Res,2018,8(12):2359-2376.
［12］　刘梦桐，柳剑英，苏静.CDKN2A基因在黑色素瘤中的研究现状［J］.中华病理学杂志，2019，48（11）：909-912.
［13］　PADHI S S,ROY S,KAR M,et al.Role of CDKN2A/p16 expre-ssion in the prognostication of oral squamous cell carcinoma［J］.Oral Oncol,2017,73:27-35.
［14］　HATZISTERGOS K E,WILLIAMS A R,DYKXHOORN D,et al.Tumor suppressors RB1 and CDKN2a cooperatively regulate cell-cycle progression and differentiation during cardiomyocyte deve-lopment and repair［J］.Circ Res,2019,124(8):1184-1197.
［15］　方乐平，徐晓燕，姬玉，等.胰腺癌术后影响患者预后的相关因素分析［J］.中华医学杂志，2018，98（8）：606-611.

相似文献/References:

[1]李　丽,赵江海.立体定向低分割适形放射治疗胰腺癌38 例临床观察与护理[J].新乡医学院学报,2006,23(06):626.
[2]刘宝军,周建华,包金英.替吉奥用于转移性胰腺癌治疗的研究进展[J].新乡医学院学报,2012,29(01):000.
[3]彭青侠,许小凡,段丽芳,等.细胞外囊泡在胰腺癌中的作用研究进展[J].新乡医学院学报,2021,38(9):893.[doi:10.7683/xxyxyxb.2021.09.021]
[4]熊慧敏,许小凡,段丽芳,等.白细胞介素-6在胰腺炎症和肿瘤中的作用机制研究进展[J].新乡医学院学报,2019,36(12):1191.[doi:10.7683/xxyxyxb.2019.12.022]
[5]田龙夫,崔云峰,张　琦,等.天然植物中生物碱类药物抗胰腺癌作用的研究进展[J].新乡医学院学报,2018,35(4):343.[doi:10.7683/xxyxyxb.2018.04.023]
　N/A.N/A[J].Journal of Xinxiang Medical University,2018,35(6):343.[doi:10.7683/xxyxyxb.2018.04.023]
[6]贾如江,侯丽艳,尹清臣,等.轴突诱导因子4D和血管内皮生长因子在胰腺癌组织中的表达[J].新乡医学院学报,2016,33(11):950.[doi:10.7683/xxyxyxb.2016.11.004]
　JIA Ru-jiang,HOU Li-yan,YIN Qing-chen,et al.Clinical significance of the expression of semaphorin 4D and vascular endothelial growth factor in pancreatic carcinoma[J].Journal of Xinxiang Medical University,2016,33(6):950.[doi:10.7683/xxyxyxb.2016.11.004]

更新日期/Last Update: 2021-06-05